Colon cancer patients who remain cancer-free for six years after surgery can be considered cured, according to a new study of more than 35,000 patients—potentially ending decades of uncertainty about when survivors can stop fearing recurrence.
“This helps us define a practical point at which a patient can be considered effectively ‘cured,'” Dr. Krushangi Patel, a medical oncologist at City of Hope cancer treatment center in Long Beach, California, who was not involved in the study, told The Epoch Times.
What the Study Found
The study, published in JAMA Oncology, examined data from 15 phase 3 randomized clinical trials that included more than 35,000 patients with stage 2 and stage 3 colon cancer. All the patients had surgery to remove their cancer and received adjuvant chemotherapy. The data followed patient outcomes for at least six years.
From one to 10 years after treatment, the cancer recurrence rate never exceeded 0.5 percent. Overall, the study found that cancer recurrence rates of less than 0.5 percent occurred six years after the patients had surgery.
In light of the findings, the researchers believe that when a person reaches six years post-surgery without a relapse, he or she can be considered cured.
They suggest that it is safe to discontinue cancer-related follow-up when patients reach this milestone, which could improve quality of life and reduce health care costs.
“A recurrence rate less than 0.5% occurred after 6 years from surgery, supporting a practical definition of cure,” the study’s authors wrote. “Recognizing this milestone may improve patient communication, guide follow-up duration, and reduce unnecessary long-term surveillance.”
What This Means for Patients and Doctors
The study’s authors, who are also oncologists, noted that as clinicians, they have a duty to tell a patient they are cured if it’s beyond a reasonable doubt that they have reached specific milestones.
This knowledge empowers people who have endured colon cancer treatments to fully embrace their recovery and experience significant psychological benefits, such as less anxiety and increased peace of mind.
“Recognizing the point at which true recurrences are extremely unlikely can improve patient communication, reduce anxiety about long-term recurrence, and allow us to tailor follow-up care more appropriately rather than continuing intensive surveillance indefinitely,” Patel said.
Study Limitations
Despite the encouraging findings, the study had some limitations. Treatments and follow-up schedules varied among patients in the trials, and information about other primary cancer tumors was limited, which could have affected the results.
Additionally, although a cancer relapse risk of less than 0.5 percent is considered extremely low by medical standards, individual patients may have different perspectives on what a small risk of recurrence means for them.
“The results of this pooled analysis are very important for both clinicians and patients,” Patel said.
She added that overall, this study offers reassurance to patients and guidance for clinicians in planning long-term survivorship care.